Last reviewed · How we verify
US-licensed epoetin alfa
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor.
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
At a glance
| Generic name | US-licensed epoetin alfa |
|---|---|
| Also known as | Epogen®, Procrit® |
| Sponsor | Sandoz |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Nephrology |
| Phase | Phase 3 |
Mechanism of action
This results in an increase in red blood cell production, which can help alleviate anemia in patients with chronic kidney disease or those undergoing chemotherapy. Epoetin alfa is a recombinant form of human erythropoietin, a hormone that plays a crucial role in regulating red blood cell production.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with chemotherapy
Common side effects
- Thromboembolism
- Hypertension
- Headache
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US-licensed epoetin alfa CI brief — competitive landscape report
- US-licensed epoetin alfa updates RSS · CI watch RSS
- Sandoz portfolio CI